AstraZeneca Names Former Genentech Executive as EVP of Global Medicines Development

From DCAT Value Chain Insights (VCI)

By People On The Move posted 08-24-2015 13:55


AstraZeneca has appointed Sean Bohen MD, PhD, as executive vice president of global medicines development and chief medical officer. He will join the company on September 15, 2015. He will be a member of AstraZeneca's senior executive team and will report to AstraZeneca Chief Executive Officer Pascal Soriot.

Dr. Bohen will be responsible for driving the progress of AstraZeneca’s portfolio of small molecules and biologics investigational medicines through late-stage development to regulatory approval. As chief medical officer, he will be responsible for patient safety across the entire AstraZeneca and Medimmune portfolio.

Dr. Bohen joins AstraZeneca from Genentech, where he was most recently senior vice president of early development. He oversaw preclinical and clinical development programs across all therapy areas, including oncology, respiratory, and autoimmune diseases, to deliver trial-ready drug candidates to late-stage development. Before this, he held a number of positions in early and late-stage development, playing a key role in the growth and progress of the Genentech/Roche portfolio. Prior to joining Genentech, Dr. Bohen was a clinical instructor in oncology at Stanford University School of Medicine, a research associate at the Howard Hughes Medical Institute, and a postdoctoral fellow at the National Cancer Institute.

Source: AstraZeneca


Thank you for reading DCAT Value Chain Insights (VCI), an information resource from the
Drug, Chemical & Associated Technologies Association (DCAT). 

Learn more and sign up to receive a complimentary subscription